Latest News and Press Releases

CHAPEL HILL, N.C., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...

CHAPEL HILL, N.C., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...

—More than 20 percent of adult CABP patients failed initial antibiotic monotherapy, including approximately one of four elderly patients— —Average U.S. macrolide resistance to S. pneumoniae...

— Pre/post treatment biopsies confirm mean NAS reduction of 1.3 points after 90 days of treatment with solithromycin — — All six patients showed ALT reductions after 90 days of treatment with...

CHAPEL HILL, N.C., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...

CHAPEL HILL, N.C., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...

— Both pivotal Phase 3 studies now published in leading infectious disease journals — — FDA and EMA currently reviewing marketing applications for solithromycin for CABP in U.S. and EU — CHAPEL...

CHAPEL HILL, N.C., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...

CHAPEL HILL, N.C., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...

Current cash balance now expected to fund operations through 2017 Management to host webcast and conference call today at 4:30 p.m. EDTCHAPEL HILL, N.C., Aug. 01, 2016 (GLOBE NEWSWIRE) -- ...